<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35565" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Toxic and Nutritional Optic Neuropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Margolin</surname>
            <given-names>Edward</given-names>
          </name>
          <aff>University of Toronto</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Blair</surname>
            <given-names>Kyle</given-names>
          </name>
          <aff>Advocate Lutheran General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shemesh</surname>
            <given-names>Ari</given-names>
          </name>
          <aff>University of Toronto</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edward Margolin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kyle Blair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ari Shemesh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35565.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Toxic and nutritional optic neuropathy both present with symmetric and progressive bilateral vision loss, decreased color vision, central or cecocentral scotomas on formal visual field testing, and the absence of a relative afferent pupillary defect. In most cases, vision loss progresses over months rather than days to weeks, and visual acuity worsens slowly. A thorough history is crucial to making a diagnosis. Specifically, any patient presenting with slow, bilateral symmetric vision loss should be asked about exposure to drugs, alcohol use, tobacco use, dietary intake, and occupational background. This activity reviews the evaluation and management of toxic and nutritional optic neuropathy and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the typical presentation of toxic and nutritional optic neuropathy.</p></list-item><list-item><p>Explain how to evaluate for toxic and nutritional optic neuropathy.</p></list-item><list-item><p>Outline the management of toxic and nutritional optic neuropathy.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving coordination and communication to advance the management of toxic and nutritional optic neuropathy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35565&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35565">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35565.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Toxic and nutritional optic neuropathies both present clinically with symmetric progressive bilateral vision loss, decreased color vision, central or cecocentral scotomas on formal visual field testing, and no relative afferent pupillary defect because of the symmetric nature of optic nerve involvement.<xref ref-type="bibr" rid="article-35565.r1">[1]</xref><xref ref-type="bibr" rid="article-35565.r2">[2]</xref>&#x000a0;</p>
        <p>In most cases, vision loss progresses over months rather than days to weeks, and vision decreases slowly.&#x000a0;A thorough history is crucial to making a diagnosis. Specifically, exposure to drugs, alcohol and tobacco use, dietary intake, and occupational background should be investigated in any patient presenting with bilateral symmetric slow visual loss.</p>
        <p>Early in the disease, optic nerves usually appear normal or, on occasion, slightly hyperemic. Continued exposure to a toxic substance or nutrient&#x000a0;deficiency would cause the slow appearance of bilateral temporal optic disc pallor due to the injury of ganglion cell axons, specifically in the papillomacular nerve fiber bundle. This would eventually lead to the diffuse pallor of the optic disc. If an obvious visual field defect is not shown on routine 30-2 perimetry, central 10-2 perimetry will demonstrate central or cecocentral scotomas.<xref ref-type="bibr" rid="article-35565.r3">[3]</xref><xref ref-type="bibr" rid="article-35565.r4">[4]</xref><xref ref-type="bibr" rid="article-35565.r5">[5]</xref></p>
      </sec>
      <sec id="article-35565.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Nutritional Optic Neuropathy</bold>
</p>
        <p>Nutritional optic neuropathy is usually sporadic; however, it has been described as an epidemic during times of war and/or famine.<xref ref-type="bibr" rid="article-35565.r6">[6]</xref><xref ref-type="bibr" rid="article-35565.r7">[7]</xref><xref ref-type="bibr" rid="article-35565.r8">[8]</xref>&#x000a0;</p>
        <p>The role of vitamin B12, &#x000a0;folic acid, and copper deficiencies in nutritional optic neuropathy is well established. Although multivitamin supplementation in malnourished people is paramount, there is no clear evidence that&#x000a0;deficiencies of thiamine, niacin, riboflavin, and pyridoxine are the primary causes of nutritional optic neuropathy.</p>
        <p><italic toggle="yes">B12-deficiencies</italic> (probably the most common culprit of nutritional optic neuropathies) result from the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pernicious anemia</p>
          </list-item>
          <list-item>
            <p>Advanced age due to the presence of atrophic gastritis and food-cobalamin malabsorption</p>
          </list-item>
          <list-item>
            <p>Gastric acid reduction therapy used commonly for the treatment of gastroesophageal reflux disease</p>
          </list-item>
          <list-item>
            <p>History of gastric surgery, gastrointestinal diseases such as celiac disease</p>
          </list-item>
          <list-item>
            <p>Parasitic infestation by tapeworms</p>
          </list-item>
          <list-item>
            <p>Alcoholism, with its resultant nutrient deficiencies and gastric malabsorption</p>
          </list-item>
          <list-item>
            <p>Nitrous oxide toxicity</p>
          </list-item>
          <list-item>
            <p>Rarely, strict veganism</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Folate deficiency</italic> can result from:</p>
        <list list-type="bullet">
          <list-item>
            <p>Decreased uptake (it is quite rare and associated with a very poor diet)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased demand (pregnancy and diseases associated with rapid cell proliferation such as hemolysis and leukemia)</p>
          </list-item>
          <list-item>
            <p>Malabsorption (alcoholism and its associated nutritional malabsorption, gastrointestinal (GI) diseases which also result in reduced absorption of dietary folic acids such as jejunal diseases and short bowel syndrome)</p>
          </list-item>
          <list-item>
            <p>Treatment with folate antagonists (such as methotrexate and trimethoprim sulfa).</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Copper deficiency</italic> is usually caused by gastric surgery and its resultant malabsorption syndromes, GI disease, total parenteral nutrition, and enteral feeding, and rarely it may be secondary to acquired dietary deficiency. Zinc toxicity can also result in copper deficiency and can result from the inadvertent ingestion of denture cream.</p>
        <p>
<bold>Toxic Optic Neuropathy</bold>
</p>
        <p>The use of toxic medications as well as ingestion or inhalation of toxic substances can both cause toxic optic neuropathy.</p>
        <p>Clinical suspicion of toxin injection should prompt investigation for the presence and levels of specific toxins in the blood, urine, and sometimes hair.</p>
        <p>Below, toxicities secondary to specific medications and substances are discussed.&#x000a0;</p>
        <p>
<bold>Ethambutol</bold>
</p>
        <p>Ethambutol is an antimycobacterial drug and is the cause of the most commonly encountered toxic optic neuropathy, with a globally-estimated incidence of at least 100,000 patients.</p>
        <p>All patients with suspected ethambutol toxicity must be assessed for the secondary invasion of optic nerves by tuberculosis with an MRI of the brain and orbits with contrast administration as well as lumbar puncture before ethambutol is held responsible for visual loss, although in cases with infiltrative optic neuropathy visual loss would rarely be very symmetric.</p>
        <p>Ethambutol toxicity is both dose-dependent (usually occurring in patients using at least 35 mg/kg per dose of the drug) and duration-dependent (almost never occurring less than two months after initiating drug therapy, with the mean onset of duration being seven months after the start of treatment).</p>
        <p>The risk of ocular ethambutol toxicity is higher in patients older than 65 years of age, with low body mass index (BMI), abnormally increased glomerular filtration rate (for example, patients with renal tuberculosis), and HIV positive patients.</p>
        <p>As in other patients with toxic-nutritional optic neuropathies, the most common visual field defect on formal perimetry testing is central or ceco-central scotomas; although, any nerve fiber bundle defect and rarely, bitemporal defects can be seen.</p>
        <p>The fundoscopy is usually normal even in the presence of decreased central vision, but bilateral optic nerve pallor would eventually develop if the injection of the medication continues.&#x000a0;</p>
        <p>Importantly, in patients with optic neuropathy secondary to ethambutol, prompt discontinuation of medication after toxicity has been recognized often leads to eventual visual improvement that can continue for up to 6 months after the cessation of the drug therapy.&#x000a0;&#x000a0;</p>
        <p>
<bold>Methanol</bold>
</p>
        <p>Unlike that of other toxins, the clinical picture of methanol optic neuropathy is acute in nature, with the development of central visual loss soon after methanol injection.</p>
        <p>In epidemic and sporadic settings, the patient usually inadvertently ingests the toxin that is often present in home-distilled alcoholic beverages. Other sources of methanol intoxication include the intake of paint solvents, gasoline additives, antifreeze, windshield fluid, and copy machine fluid. Methanol is also sometimes injected in suicide attempts.</p>
        <p>The first manifestations of methanol injection are GI symptoms such as nausea and vomiting. Subsequently, the patient experiences headache, shortness of breath, abdominal pain, confusion, and visual loss of any degree. Coma and death may ensue. In patients with severe visual impairment, the pupils may be dilated and non-reactive to light.</p>
        <p>The funduscopic examination reveals a hyperemic optic disc with edema in the acute stage. Supporting biochemical evidence of acute methanol toxicity is high anion gap metabolic acidosis due to the accumulation of formate, a metabolite of methanol. A serum level of methanol greater than 20 mg/dL establishes a diagnosis.</p>
        <p>The primary drug used to treat acute methanol toxicity is fomepizole, an inhibitor of alcohol dehydrogenase, the enzyme that oxidizes methanol to formate. Folate supplementation, hyperventilation if the patient is intubated, sodium bicarbonate administration for patients with serum pH lesser than 7.3, and hemodialysis for patients with renal failure or pH lesser than 7.3 should also be utilized.</p>
        <p>
<bold>Amiodarone</bold>
</p>
        <p>Amiodarone, an antiarrhythmic drug, has been arguably associated with sequential or bilateral anterior optic neuropathy simulating non-arteritic anterior ischemic optic neuropathy (NAION).</p>
        <p>Clinical characteristics of amiodaron-associated optic neuropathy are gradually progressive unilateral or bilateral vision loss, prolonged bilateral optic disc swelling, and sometimes, the halt of visual loss when amiodarone is stopped.</p>
        <p>In patients who develop optic neuropathy while receiving amiodarone and in those patients that other treatable causes have been excluded, cardiology consultation regarding discontinuation of the drug should be sought since there is a potential for some vision recovery if the drug is discontinued.</p>
        <p>Currently, there is no sufficient evidence to recommend regular screening of all patients receiving amiodarone for the presence of optic neuropathy. &#x000a0;</p>
        <p>
<bold>Tobacco and Alcohol</bold>
</p>
        <p>Alcohol is no longer considered to cause toxic optic neuropathy, but alcoholism is associated with a much higher incidence of nutritional deficiencies, some of which can cause optic neuropathy.</p>
        <p>Toxic optic neuropathy attributed to smoking (especially cigar or pipe smoking) is a diagnosis of exclusion, and other etiologies, including mitochondrial optic neuropathies, for example, Leber&#x02019;s hereditary&#x000a0;optic neuropathy (LHON), should be explored.</p>
        <p>In the early 1990s, there was an epidemic of optic and peripheral neuropathy in Cuba associated with famine. Patients presented with features typical of toxic/nutritional optic neuropathies: symmetric visual loss, decreased color vision, cecal and cecocentral scotomas on visual field testing, optic nerve pallor, and nerve fiber layer thinning. Over 51,000 people were affected, and the prevailing theory was that these patients harbored mitochondrial mutations, which predisposed them to the optic and peripheral neuropathy brought on by the nutritional deficiencies. However, most of the affected patients did not have one of the LHON mutations. It was concluded that Cuban epidemic optic neuropathy (CEON)&#x000a0;may have been secondary to another yet undiscovered mitochondrial DVA mutation or be an acquired variety of mitochondrial dysfunction brought on by severe nutritional deficiencies in patients with underlying yet unidentified mitochondrial DNA mutations.</p>
      </sec>
      <sec id="article-35565.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Nutritional optic neuropathy is more prevalent during the time of war and famine and is more prevalent in patients who are at risk of having poor nutritional intake, for example, alcoholics and patients who are socially marginalized.</p>
        <p>Toxic optic neuropathy prevalence varies depending on the toxic substance. For instance, in a large retrospective study of 857 patients taking ethambutol, 1.5% were found to have ethambutol toxic optic neuropathy. In another large prospective study of 837 patients taking amiodarone, the maximum annual incidence rate of bilateral visual loss, which was attributed to amiodarone, was 0.13%.</p>
      </sec>
      <sec id="article-35565.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of toxic and nutritional optic neuropathies has been thought to be secondary to the damage of ganglion cell axons in the papillomacular bundle resulting in central and cecocentral defects on formal visual field testing. Specific pathophysiology varies depending on the toxic substance.</p>
      </sec>
      <sec id="article-35565.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with toxic and nutritional optic neuropathies typically present with slow and insidious bilateral and very symmetric visual loss. The exception to this is methanol-related optic neuropathy, where the visual loss follows methanol injection. Patients may report decreased vision, visual field defects, difficulty seeing in low-light conditions, and decreased visualization of colors. Early in the disease process, The optic disc often appears normal on the fundus exam. Late in the disease process, there is&#x000a0;diffuse pallor of the optic disc and thinning of the retinal nerve fiber layer.<xref ref-type="bibr" rid="article-35565.r9">[9]</xref></p>
      </sec>
      <sec id="article-35565.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When a patient with bilateral and symmetric optic neuropathy is encountered, it is recommended that the following tests be routinely performed:</p>
        <list list-type="bullet">
          <list-item>
            <p>Blood tests for vitamin B12 levels and serum cobalamin levels</p>
          </list-item>
          <list-item>
            <p>Levels of vitamin B12 metabolites (serum methylmalonic acid and plasma total homocysteine)</p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC) with smear analysis to rule out anemia, macrocytosis, and neutrophil hypersegmentation</p>
          </list-item>
          <list-item>
            <p>Levels of intrinsic factor and parietal cell antibodies to rule out pernicious anemia</p>
          </list-item>
          <list-item>
            <p>Red blood cell folate levels are a more reliable indicator of tissue stores than serum folate levels)</p>
          </list-item>
          <list-item>
            <p>Plasma total homocysteine level</p>
          </list-item>
        </list>
        <p>To investigate the presence of copper deficiency, serum, and urinary copper levels, as well as various hematologic parameters like anemia, and neutropenia, the presence of vacuolated myeloid precursors and ringed sideroblasts should be checked. Levels of niacin, riboflavin, pyridoxine, and thiamine should also be tested in all patients to assess for vitamin deficiencies.<xref ref-type="bibr" rid="article-35565.r10">[10]</xref><xref ref-type="bibr" rid="article-35565.r9">[9]</xref></p>
      </sec>
      <sec id="article-35565.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of the nutritional or toxic optic neuropathy is based on the cause. Nutritional supplements will need to be given in cases of nutritional optic neuropathy. If the supplement cannot be absorbed in an oral form, then it may have to be administered parentally.&#x000a0;Medications causing optic nerve toxicity should be discontinued unless the benefits of continuing the medication outway the risk of further optic nerve damage. The specialist prescribing the medication should be consulted to provide recommendations for alternate therapies. Patients should be encouraged to limit or discontinue the use of alcohol and tobacco products to reduce the risk of worsening optic neuropathy.</p>
      </sec>
      <sec id="article-35565.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>All patients presenting with a bilateral low progressive symmetric visual loss should be investigated for the presence of maculopathies, which can usually be excluded by performing intravenous fluorescence angiography and multifocal electroretinogram (ERG).</p>
        <p>Hereditary optic neuropathies such as dominant optic atrophy and Leber's hereditary optic neuropathy can also present similarly to toxic or nutritional optic neuropathies; thus, the genetic tests to exclude these conditions should be performed in all patients suspected of having toxic/nutritional optic neuropathies.</p>
        <p>Depending on a patient's clinical presentation and if demyelination, compression, infiltration, and ischemia are suspected to be the causes of visual loss, an MRI of the brain and orbits with contrast administration, targeted serological testing, and occasionally, lumbar puncture should be performed.&#x000a0;Note that the visual loss is usually acute and not symmetric in these etiologies.</p>
        <p>In patients with normal-appearing optic nerves, no thinning of the peripapillary retinal nerve fiber layer and normal ganglion cell analysis on ocular coherence tomography, the presence of decreased central acuities with no relative afferent pupillary defect, and constricted visual fields likely indicate a nonorganic visual loss.</p>
      </sec>
      <sec id="article-35565.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The visual prognosis of toxic and nutritional optic neuropathy is variable and is dependent on the cause and severity of the initial optic nerve insult. One systematic review found that in patients with B12 deficiency optic neuropathy, there was improved visual acuity after oral B12 supplementation in greater than 50% of patients with the diagnosis. However, a small percentage of patients progressed to blindness.<xref ref-type="bibr" rid="article-35565.r11">[11]</xref>&#x000a0;</p>
        <p>Methanol-induced toxic optic neuropathy shows resolution of visual disturbances in two to three weeks after intoxication in most patients. However, around a third or more of patients develop permanent visual defects.<xref ref-type="bibr" rid="article-35565.r12">[12]</xref>&#x000a0;Nutritional optic neuropathy associated with folate deficiency has a good visual prognosis if treated within a few months after symptoms develop.<xref ref-type="bibr" rid="article-35565.r13">[13]</xref>&#x000a0;The prognosis of tobacco and alcohol-induced optic neuropathy is variable, with milder symptoms and duration portending a better prognosis.<xref ref-type="bibr" rid="article-35565.r14">[14]</xref></p>
      </sec>
      <sec id="article-35565.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients started on ethambutol should be educated on the risks of toxic optic neuropathy. Other patients at risk for a toxic optic neuropathy, including patients who abuse alcohol, and tobacco users,&#x000a0;who are starting amiodarone, should be taught about the risks for optic nerve damage. Patients at risk for nutritional optic neuropathy should be educated about symptoms of vision decrease and follow up with an ophthalmologist. This includes patients undergoing gastric bypass surgery, starting methotrexate therapy, and being diagnosed with pernicious anemia. Vitamin deficiencies often can be deterred with initial nutritional supplementation.<xref ref-type="bibr" rid="article-35565.r15">[15]</xref></p>
      </sec>
      <sec id="article-35565.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When a patient is suspected of having toxic or nutritional optic neuropathy,&#x000a0;a prompt&#x000a0;referral to an ophthalmologist is recommended. [Level V] All patients presenting with a bilateral progressive symmetric visual loss should be investigated for the presence of maculopathies, which can usually be excluded by performing intravenous fluorescence angiography and multifocal ERG.&#x000a0;Hereditary optic neuropathies such as dominant optic atrophy and Leber's hereditary optic neuropathy can also present similarly to toxic or nutritional optic neuropathies; thus, the genetic tests to exclude these conditions should be performed in all patients suspected of having toxic/nutritional optic neuropathies.&#x000a0;</p>
        <p>In a toxic optic neuropathy due to medication, there should be communication with the prescribing physician to discontinue the offending agent. In any toxic or nutritional optic neuropathy, the patient's&#x000a0;primary care provider should be notified to initiate the correct treatment. Other healthcare providers that may be involved include nursing, social work, radiology, neurology, psychiatry, addiction medicine, gastroenterology, rheumatology, cardiology, and internal medicine.</p>
        <p>Depending on a patient's clinical presentation and when demyelination, compression, infiltration, and ischemia are suspected to be the causes of visual loss, an MRI of the brain and orbits with contrast administration, targeted serological testing, and occasionally, lumbar puncture should be performed.&#x000a0;The outcomes after optic neuropathy depend on the cause. While most drug and nutritionally induced optic neuropathy can reverse when the offending agent is discontinued, some degree of vision loss may persist in a few patients.</p>
      </sec>
      <sec id="article-35565.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35565&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35565">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/toxic-and-nutritional-optic-neuropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=35565">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35565/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35565">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35565.s14">
        <title>References</title>
        <ref id="article-35565.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Quevedo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santiesteban-Freixas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eells</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sadun</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Cuban Epidemic Neuropathy: Insights into the Toxic-Nutritional Hypothesis through International Collaboration.</article-title>
            <source>MEDICC Rev</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>27</fpage>
            <page-range>27-31</page-range>
            <pub-id pub-id-type="pmid">29773773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez Salda&#x000f1;a</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galvis Trujillo</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Borbolla Pertierra</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mondrag&#x000f3;n Pineda</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Ju&#x000e1;rez Olgu&#x000ed;n</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Linezolid-associated optic neuropathy in a pediatric patient with Mycobacterium nonchromogenicum: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>50</issue>
            <fpage>e9200</fpage>
            <pub-id pub-id-type="pmid">29390337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>N&#x000ed; Mh&#x000e9;al&#x000f3;id</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Cunniffe</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis secondary to antiandrogen therapy.</article-title>
            <source>Ir J Med Sci</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>186</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-570</page-range>
            <pub-id pub-id-type="pmid">28039596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieira</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Dias dos Santos</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>dos Anjos</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Borges</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Amado</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>da Cunha</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Retinal Ganglion Cell Layer Analysis by Optical Coherence Tomography in Toxic and Nutritional Optic Neuropathy.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-5</page-range>
            <pub-id pub-id-type="pmid">25724010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grzybowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Z&#x000fc;lsdorff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilhelm</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tonagel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Toxic optic neuropathies: an updated review.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>402</fpage>
            <page-range>402-410</page-range>
            <pub-id pub-id-type="pmid">25159832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mustafa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Approach to diagnosis and management of optic neuropathy.</article-title>
            <source>Neurol India</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>599</fpage>
            <page-range>599-605</page-range>
            <pub-id pub-id-type="pmid">25591670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Stavern</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Metabolic, hereditary, traumatic, and neoplastic optic neuropathies.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>4 Neuro-ophthalmology</issue>
            <fpage>877</fpage>
            <page-range>877-906</page-range>
            <pub-id pub-id-type="pmid">25099099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Riordan-Eva</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hadden</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Subacute peripheral and optic neuropathy syndrome with no evidence of a toxic or nutritional cause.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>115</volume>
            <issue>8</issue>
            <fpage>1389</fpage>
            <page-range>1389-93</page-range>
            <pub-id pub-id-type="pmid">23384546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behbehani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical approach to optic neuropathies.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-46</page-range>
            <pub-id pub-id-type="pmid">19668477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lloyd</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fraunfelder</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced optic neuropathies.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>827</fpage>
            <page-range>827-36</page-range>
            <pub-id pub-id-type="pmid">18174968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bint I Bilal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shabir Chaudhry</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fatima Malik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Choudry</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhaskaran Kartha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Optic neuropathy as a presenting feature of vitamin B-12 deficiency: A systematic review of literature and a case report.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>60</volume>
            <fpage>316</fpage>
            <page-range>316-322</page-range>
            <pub-id pub-id-type="pmid">33204422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nurieva</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Diblik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kuthan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sklenka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meliska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bydzovsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heissigerova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kotikova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Navratil</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Komarc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seidl</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vaneckova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pelclova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zakharov</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Progressive Chronic Retinal Axonal Loss Following Acute Methanol-induced Optic Neuropathy: Four-Year Prospective Cohort Study.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>191</volume>
            <fpage>100</fpage>
            <page-range>100-115</page-range>
            <pub-id pub-id-type="pmid">29709459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yukawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kohriyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mimori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Folic acid-responsive neurological diseases in Japan.</article-title>
            <source>J Nutr Sci Vitaminol (Tokyo)</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-7</page-range>
            <pub-id pub-id-type="pmid">11575572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiotoroiu</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Noaghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stefaniu</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Secureanu</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Purcarea</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Zemba</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tobacco-alcohol optic neuropathy--clinical challenges in diagnosis.</article-title>
            <source>J Med Life</source>
            <year>2014</year>
            <season>Oct-Dec</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>472</fpage>
            <page-range>472-6</page-range>
            <pub-id pub-id-type="pmid">25713605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35565.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baj</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kobak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tyczy&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Maani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teresi&#x00144;ski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buszewicz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Januszewski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Flieger</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Toxic and Nutritional Optic Neuropathies-An Updated Mini-Review.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2022</year>
            <month>Mar</month>
            <day>06</day>
            <volume>19</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35270784</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
